Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Fong, Jason T ^a   Jacobs, Ryan J ^a   Moravec, David N ^a   Uppada, Srijayaprakash B ^a   Botting, Gregory M ^a   Nlend, Marie ^b   Puri, Neelu ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Thermo Fisher Scientific   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TIVANTINIB; UNCLASSIFIED DRUG; WNT PROTEIN; XAV 939;

ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOLECULAR MECHANICS; SIGNAL TRANSDUCTION; UPREGULATION; WNT SIGNALING PATHWAY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INDOLES; LUNG NEOPLASMS; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SIROLIMUS; SULFONAMIDES; TOR SERINE-THREONINE KINASES; WNT PROTEINS;

EID: 84892607231     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078398     Document Type: Article

References (64)

1. Puri N, Salgia R (2008) Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog 7: 9.
2. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
3. Stella MC, Comoglio PM (1999) HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol 31: 1357-1362.
4. Xu Y, Liu H, Chen J, Zhou Q (2010) Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib. Cancer Biol Ther 9: 572-582.
5. Sierra JR, Cepero V, Giordano S (2010) Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 9: 75.
6. Bean J, Brennan C, Shih JY, Riely G, Viale A, et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104: 20932-20937.
7. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, et al. (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17: 77-88.
8. Gazdar AF (2009) Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 Suppl 1: S24-31.
9. Dienstmann R, De Dosso S, Felip E, Tabernero J (2011) Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Mol Oncol.
10. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, et al. (2003) A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 63: 5462-5469.
11. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, et al. (2005) Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65: 1479-1488.
12. Munshi N, Jeay S, Li Y, Chen CR, France DS, et al. (2010) ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 9: 1544-1553.
13. Laux I, Goldman J, Just R, Brady K, Li J, et al. (2009) Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib. Journal of Clinical Oncology 27:3549.
14. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, et al. (2011) Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol 29: 3307-3315.
15. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, et al. (2011) Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. Clin Oncol 29: abstr 7505.
16. Bianco R, Damiano V, Gelardi T, Daniele G, Ciardiello F, et al. (2007) Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. Curr Pharm Des 13: 3358-3367.
17. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, et al. (2000) Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 275: 8806-8811.
18. Xu KP, Yu FS (2007) Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing. Invest Ophthalmol Vis Sci 48: 2242-2248.
19. Reznik TE, Sang Y, Ma Y, Abounader R, Rosen EM, et al. (2008) Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res 6: 139-150.
20. Spix JK, Chay EY, Block ER, Klarlund JK (2007) Hepatocyte growth factor induces epithelial cell motility through transactivation of the epidermal growth factor receptor. Exp Cell Res 313: 3319-3325.
21. Ramalingam S, Forster J, Naret C, Evans T, Sulecki M, et al. (2008) Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. J Thorac Oncol 3: 258-264.
22. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM (2004) Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64: 5355-5362.
23. Gilmer TM, Cable L, Alligood K, Rusnak D, Spehar G, et al. (2008) Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. Cancer Res 68: 571-579.
24. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, et al. (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 119: 3000-3010.
25. Ma PC, Schaefer E, Christensen JG, Salgia R (2005) A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res 11: 2312-2319.
26. Schmid K, Bago-Horvath Z, Berger W, Haitel A, Cejka D, et al. (2010) Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. Br J Cancer 103: 622-628.
27. Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, et al. (2006) Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5: 2676-2684.
28. La Monica S, Galetti M, Alfieri RR, Cavazzoni A, Ardizzoni A, et al. (2009) Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol 78: 460-468.
29. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, et al. (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487: 505-509.
30. Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, et al. (2001) Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol 152: 87-96.
31. Hu T, Li C (2010) Convergence between Wnt-beta-catenin and EGFR signaling in cancer. Mol Cancer 9: 236.
32. Ji H, Wang J, Nika H, Hawke D, Keezer S, et al. (2009) EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell 36: 547-559.
33. Sharma M, Chuang WW, Sun Z (2002) Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J Biol Chem 277: 30935-30941.
34. Suzuki M, Shigematsu H, Nakajima T, Kubo R, Motohashi S, et al. (2007) Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer. Clin Cancer Res 13: 6087-6092.
35. Casas-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, et al. (2012) Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res.
36. Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, et al. (2002) Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 8: 620-627.
37. Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, et al. (2007) c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 13: 2246-2253.
38. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
39. Milligan SA, Burke P, Coleman DT, Bigelow RL, Steffan JJ, et al. (2009) The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res 15: 4885-4894.
40. Coley HM (2004) Development of drug-resistant models. Methods Mol Med 88: 267-273.
41. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181.
42. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
43. Yun MS, Kim SE, Jeon SH, Lee JS, Choi KY (2005) Both ERK and Wnt/beta-catenin pathways are involved in Wnt3a-induced proliferation. J Cell Sci 118: 313-322.
44. Mazieres J, He B, You L, Xu Z, Jablons DM (2005) Wnt signaling in lung cancer. Cancer Lett 222: 1-10.
45. Jeon SH, Yoon JY, Park YN, Jeong WJ, Kim S, et al. (2007) Axin inhibits extracellular signal-regulated kinase pathway by Ras degradation via beta-catenin. J Biol Chem 282: 14482-14492.
46. Fu Y, Zheng S, An N, Athanasopoulos T, Popplewell L, et al. (2011) beta-catenin as a potential key target for tumor suppression. Int J Cancer 129: 1541-1551.
47. Jiang BH, Liu LZ (2008) Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 11: 63-76.
48. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, et al. (2006) Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12: 6494-6501.
49. Wedel S, Hudak L, Seibel JM, Juengel E, Tsaur I, et al. (2011) Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells. Cancer Lett 301: 17-28.
50. Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, et al. (2010) The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition. Mol Cancer Res 8: 1142-1151.
51. Zhu H, Cheng H, Ren Y, Liu ZG, Zhang YF, et al. (2011) Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo. Mol Biol Rep.
52. Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, et al. (2012) Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer.
53. Zhou W, Ercan D, Chen L, Yun CH, Li D, et al. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462: 1070-1074.
54. Choo AY, Roux PP, Blenis J (2006) Mind the GAP: Wnt steps onto the mTORC1 train. Cell 126: 834-836.
55. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, et al. (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126: 955-968.
56. Civenni G, Holbro T, Hynes NE (2003) Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. EMBO Rep 4: 166-171.
57. MacDonald BT, Semenov MV, Huang H, He X (2011) Dissecting molecular differences between Wnt coreceptors LRP5 and LRP6. PLoS One 6: e23537.
58. Shahi P, Park D, Pond AC, Seethammagari M, Chiou SH, et al. (2012) Activation of Wnt signaling by chemically induced dimerization of LRP5 disrupts cellular homeostasis. PLoS One 7: e30814.
59. Mendoza MC, Er EE, Blenis J (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36: 320-328.
60. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, et al. (2001) Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 20: 8125-8135.
61. Tahir SA, Yang G, Goltsov A, Song KD, Ren C, et al. (2013) Caveolin-1-LRP6 Signaling Module Stimulates Aerobic Glycolysis in Prostate Cancer. Cancer Res 73: 1900-1911.
62. Adachi Y, Shibai Y, Mitsushita J, Shang WH, Hirose K, et al. (2008) Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6. Oncogene 27: 4921-4932.
63. Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, et al. (2008) Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 27: 596-603.
64. Weidenfeld J, Shu W, Zhang L, Millar SE, Morrisey EE (2002) The WNT7b promoter is regulated by TTF-1, GATA6, and Foxa2 in lung epithelium. J Biol Chem 277: 21061-21070.